Spots Global Cancer Trial Database for hlx10
Every month we try and update this database with for hlx10 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) | NCT04547166 | Metastatic Colo... | HLX10 HLX04、 | 18 Years - 75 Years | Shanghai Henlius Biotech | |
| A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer | NCT04139135 | Gastric Cancer | HLX10 Placebos | 18 Years - 70 Years | Shanghai Henlius Biotech | |
| Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC | NCT05513573 | Nasopharyngeal ... | HLX07 HLX10 placebo chemotherapy | 18 Years - | Shanghai Henlius Biotech | |
| A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC | NCT04465734 | Hepatocellular ... | HLX10 HLX04 Sorafenib | 18 Years - 75 Years | Shanghai Henlius Biotech | |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors | NCT03757936 | Solid Tumor | HLX04 HLX10 | 18 Years - | Shanghai Henlius Biotech | |
| A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC | NCT04033354 | Squamous Non Sm... | HLX10 carboplatin and... Placebo | 18 Years - | Shanghai Henlius Biotech | |
| Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors | NCT03468751 | Solid Tumor | HLX10 | 18 Years - | Henlix, Inc | |
| to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | NCT04301739 | Triple Negative... | HLX10 nab-paclitaxel,... Placebo | 18 Years - 70 Years | Shanghai Henlius Biotech | |
| A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. | NCT06349980 | Carcinoma, Hepa... | HLX53 (1000mg) HLX53 (2000mg) HLX10 HLX04 Placebo | 18 Years - | Shanghai Henlius Biotech | |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors | NCT05442996 | Solid Tumor, Ad... | HLX35 HLX10 | 18 Years - | Shanghai Henlius Biotech | |
| A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer | NCT05354700 | Small-cell Lung... | HLX07 HLX10 carboplatin and... | 18 Years - | Shanghai Henlius Biotech | |
| A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation | NCT05641493 | Non Small Cell ... | HLX208+HLX10 | 18 Years - 80 Years | Shanghai Henlius Biotech | |
| to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | NCT04301739 | Triple Negative... | HLX10 nab-paclitaxel,... Placebo | 18 Years - 70 Years | Shanghai Henlius Biotech | |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors | NCT03757936 | Solid Tumor | HLX04 HLX10 | 18 Years - | Shanghai Henlius Biotech | |
| HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma | NCT05290220 | Advanced Hepato... | HLX07 HLX10 HLX04 lenvatinib | 18 Years - 75 Years | Shanghai Henlius Biotech | |
| Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC | NCT05584137 | Colorectal Canc... | HLX26 HLX10 | 18 Years - | Shanghai Henlius Biotech | |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC | NCT05239650 | CRC | HLX07 HLX10 mFOLFOX6 | 18 Years - 75 Years | Shanghai Henlius Biotech | |
| A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. | NCT06349980 | Carcinoma, Hepa... | HLX53 (1000mg) HLX53 (2000mg) HLX10 HLX04 Placebo | 18 Years - | Shanghai Henlius Biotech | |
| to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | NCT04301739 | Triple Negative... | HLX10 nab-paclitaxel,... Placebo | 18 Years - 70 Years | Shanghai Henlius Biotech | |
| A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors | NCT05442996 | Solid Tumor, Ad... | HLX35 HLX10 | 18 Years - | Shanghai Henlius Biotech | |
| A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer | NCT04139135 | Gastric Cancer | HLX10 Placebos | 18 Years - 70 Years | Shanghai Henlius Biotech | |
| Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor | NCT05400265 | Adult Solid Tum... | HLX26 HLX10 | 18 Years - 75 Years | Shanghai Henlius Biotech | |
| A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer | NCT04806945 | Cervical Cancer | HLX10 Paclitaxel Cisplatin Carboplatin Placebo to HLX1... | 18 Years - 75 Years | Shanghai Henlius Biotech |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
